BALA CYNWYD, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Oppenheimer sets Larimar Therapeutics' price target at $26, anticipating $1.2 billion in global revenues by 2030. The company aims for FDA marketing application submission in late 2025, focusing on ...
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Larimar Therapeutics reports ...
The clinical hold means that Bala Cynwyd, Pennsylvania-based Larimar can’t proceed with further tests of the drug, CTI-1601, in humans, including a study that was expected to start in the second half ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback